| Literature DB >> 36204658 |
Martina Maritati1,2, Alessandro Trentini3, Davide Chemello1, Elisa Mazzoni4, Carlo Cervellati5, Gustavo Alberto Zanoli2, Carlo Contini1, Giuseppe De Rito2.
Abstract
Purpose: The success of total joint arthroplasty (TJA) has led to consistent growth in the use of arthroplasty in progressively younger patients. However, more than 10 percent of patients require revision surgery due to implant failure caused by aseptic or septic inflammation. Among the latter, surgical site infection (SSI) represents one of the worst complications of TJA, potentially resulting in the removal of the prosthesis. The aim of our study was to identify potential risk factors for SSIs in a population of patients undergoing TJA.Entities:
Mesh:
Year: 2022 PMID: 36204658 PMCID: PMC9532124 DOI: 10.1155/2022/2150804
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.529
Demographics and clinical variables for controls and cases.
| Group A ( | Group B ( | |
|---|---|---|
| Sex (female; | 478 (65) | 18 (72) |
| Age (years ± SD) | 71.2 ± 9.5 | 68.5 ± 13.7 |
| BMI (kg/m2) | 28.6 ± 5.1 | 30.4 ± 6.7 |
| Diabetes (%) | 13.3 | 9.0 |
| Number of operators | ||
| 2 | 29.0 | 24.0 |
| 3 | 56.0 | 56.0 |
| 4 | 14.7 | 20.0 |
| 5 | 0.1 | 0.0 |
| Prosthesis type (%) | ||
| Hip | 42.8 | 40.0 |
| Knee | 56.7 | 60.0 |
| Shoulder | 0.5 | 0.0 |
| Cemented (yes, %) | 57.8 | 60.0 |
| Antibiotic (%) | ||
| Cefazolin | 94.0 | 92.0 |
| Vancomycin | 6.0 | 8.0 |
| ASA score (mean ± SD) | 2.6 ± 0.5 | 2.6 ± 0.5 |
| Duration of surgery (minutes; mean ± SD) | 74 ± 19 | 76 ± 17 |
| Steroid drugs (%) | 4.4 | 4.0 |
| Anticoagulant therapy (%) | 31.2 | 31.8 |
| Hospitalization (days, mean ± SD) | 13.0 ± 2.9 | 13.0 ± 2.8 |
| Type of suture (%) | ||
| Clip | 14.7 | 20.0 |
| Absorbable stitches | 85.3 | 80.0 |
SD: standard deviation.
Laboratory parameters measured before the surgical procedure and at discharge.
| Control ( | Infected ( | |||
|---|---|---|---|---|
| Preoperative | Discharge | Preoperative | Discharge | |
| Preoperative serum albumin | 4.6 [4.4-4.8] | — | 4.5 [4.2-4.7] | — |
| Preoperative CRP | 17.0 [7.0-37.0] | 86.0 [40.0-157.0] | 21.0 [5.5-59.5] | 123.0 [69.5-176.0] |
| Pre-operative ESR | 16.0 [9.0-28.0] | 45.0 [30.0-62.0] | 12.0 [6.0-25.0] | 43.0 [27.0-63.5] |
| Total leukocytes (cells/ | 6690 [5720-8020] | 6720 [5770-7870] | 7030 [5560-8545] | 7970 [6235-9680]a |
| Neutrophils count (cells/ | 4010 [3200-4930] | 3880 [3160-4920] | 4320 [3305-5100] | 4900 [3650-5885]b |
Values are reported as median [interquartile range]; SD: standard deviation; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate. ap = 0.025 vs. control; bp = 0.016 vs. control.
Figure 1ROC curve analysis and area under the curve (AUC) calculation showing the diagnostic accuracy of total leukocyte and neutrophil's count at discharge to identify subjects at risk of developing surgical site infection (SSI). The AUC values are equal to 0.623 (p = 0.025) and 0.641 (p = 0.016), respectively.
Figure 2Change in total leucocytes (a) and neutrophils (b) in the two groups between preoperative and discharge measurements. As shown in Figure 2(a), patients who would develop infection (Figure 2(a), no squares) had a more pronounced increase in total leukocytes than uninfected subjects (p = 0.006). This interaction still exists for neutrophil's count,although it is less evident (Figure 2(b), (p = 0.019).
Figure 3Time to diagnosis of surgical site infection (SSI) (days from the operation) in relation to the three classification categories of SSI (superficial, deep, and PJI) calculated by analysis of variance (ANOVA). Deep SSI was diagnosed significantly earlier than superficial SSI (p = 0.008). This difference loses statistical significance when comparing deep SSI and prosthetic joint infections (PJIs) (p = 0.145).
Isolated pathogens and their resistance pattern.
| Pathogen | Number of isolates | Tested antibiotic | Resistance (%) |
|---|---|---|---|
|
| 4 (40%) | Methicillin | 100% |
| Fluoroquinolones | 100% | ||
|
| 2 (20%) | Fluoroquinolones | 0% |
| Cotrimoxazole | 50% | ||
|
| 1 (10%) | Methicillin | 0% |
| Fluoroquinolones | 0% | ||
| Cotrimoxazole | 0% | ||
|
| 1 (10%) | Fluoroquinolones | 0% |
|
| 1 (10%) | Fluoroquinolones | 0% |
|
| 1 (10%) | Fluoroquinolones | 0% |